Table 3

League table for failure to achieve clinical response: all Patients

UPA 45 mg0.36 (0.29–0.43)
0.66 (0.49–0.88) IFX 10 mg/kg1.05 (0.79–1.39)0.52 (0.41–0.66)
0.64 (0.47–0.88)0.98 (0.70–1.37) UST 6 mg/kg0.78 (0.61–1.01)0.56 (0.44–0.71)
0.63 (0.49–0.81)0.96 (0.75–1.23)0.98 (0.74–1.30) IFX 5 mg/kg0.81 (0.61–1.07)0.54 (0.46–0.64)
0.60 (0.46–0.79)0.92 (0.69–1.24)0.94 (0.69–1.27)0.96 (0.75–1.21) FIL 200 mg0.77 (0.64–0.92)0.59 (0.49–0.71)
0.58 (0.45–0.74)0.88 (0.67–1.17)0.90 (0.67–1.20)0.92 (0.73–1.14)0.96 (0.75–1.22) TOF 10 mg0.62 (0.53–0.73)
0.53 (0.39–0.71)0.81 (0.58–1.11)0.82 (0.59–1.15)0.84 (0.64–1.10)0.88 (0.65–1.17)0.92 (0.69–1.21) GOL 400/200 mg0.92 (0.72–1.17)0.68 (0.54–0.85)
0.52 (0.41–0.66)0.79 (0.60–1.04)0.81 (0.61–1.08)0.82 (0.67–1.02)0.86 (0.68–1.09)0.90 (0.72–1.13)0.98 (0.75–1.29) VED 300 mg 0.61 (0.48–0.79)* 0.79 (0.66–0.94)
0.51 (0.39–0.67)0.78 (0.58–1.05)0.79 (0.58–1.08)0.81 (0.64–1.03)0.85 (0.65–1.10)0.88 (0.69–1.14)0.97 (0.72–1.30)0.98 (0.77–1.25) OZA 1 mg0.70 (0.58–0.85)
0.50 (0.37–0.68)0.77 (0.56–1.06)0.78 (0.61–1.01)0.80 (0.61–1.05)0.83 (0.62–1.12)0.87 (0.66–1.15)0.95 (0.69–1.32)0.97 (0.74–1.27)0.99 (0.73–1.33) UST 130 mg0.71 (0.57–0.89)
0.48 (0.36–0.65)0.74 (0.54–1.02)0.75 (0.54–1.05)0.77 (0.59–1.01)0.80 (0.60–1.07)0.84 (0.64–1.11)0.92 (0.72–1.17)0.93 (0.71–1.22)0.95 (0.71–1.27)0.96 (0.70–1.32) GOL 200/100 mg0.74 (0.59–0.92)
0.47 (0.35–0.65)0.72 (0.52–1.01)0.74 (0.52–1.04)0.75 (0.56–1.00)0.78 (0.57–1.07)0.82 (0.61–1.10)0.90 (0.64–1.25)0.91 (0.69–1.20)0.93 (0.68–1.27)0.94 (0.67–1.31)0.98 (0.70–1.36) ADA 160/160 mg0.88 (0.71–1.10)
0.46 (0.36–0.60)0.71 (0.53–0.94)0.72 (0.54–0.97)0.73 (0.58–0.92)0.77 (0.64–0.92)0.80 (0.63–1.02)0.88 (0.66–1.16)0.89 (0.71–1.12)0.91 (0.70–1.17)0.92 (0.69–1.22)0.95 (0.72–1.26)0.98 (0.72–1.32) FIL 100 mg0.77 (0.65–0.92)
0.44 (0.35–0.56)0.68 (0.52–0.88)0.69 (0.52–0.91)0.70 (0.59–0.84)0.74 (0.59–0.92)0.77 (0.62–0.95)0.84 (0.65–1.09)0.85 (0.70–1.04)0.87 (0.69–1.09)0.88 (0.68–1.15)0.92 (0.71–1.19)0.94 (0.72–1.23)0.96 (0.77–1.19) ETR 105 mg0.97 (0.78–1.21)0.83 (0.71–0.97)
0.42 (0.33–0.52)0.64 (0.49–0.82)0.65 (0.50–0.85)0.66 (0.55–0.80)0.69 (0.55–0.86)0.72 (0.59–0.88)0.79 (0.61–1.02) 0.80 (0.68–0.95)* 0.82 (0.65–1.02)0.83 (0.64–1.07)0.86 (0.67–1.11)0.88 (0.71–1.10)0.90 (0.73–1.11)0.94 (0.80–1.10) ADA 160/80 mg0.90 (0.72–1.14)0.80 (0.70–0.91)
0.39 (0.30–0.52)0.60 (0.44–0.81)0.61 (0.45–0.84)0.62 (0.49–0.80)0.65 (0.50–0.85)0.68 (0.53–0.88)0.74 (0.55–1.01)0.76 (0.60–0.96)0.77 (0.59–1.01)0.78 (0.58–1.05)0.81 (0.60–1.09)0.83 (0.62–1.12)0.85 (0.66–1.10)0.89 (0.70–1.12)0.94 (0.77–1.15) ADA 80/40 mg0.88 (0.71–1.09)
0.36 (0.29–0.43)0.55 (0.43–0.69)0.56 (0.44–0.71)0.57 (0.49–0.66)0.59 (0.49–0.71)0.62 (0.53–0.73)0.68 (0.54–0.85)0.69 (0.59–0.80)0.70 (0.58–0.85)0.71 (0.57–0.89)0.74 (0.59–0.92)0.76 (0.59–0.97)0.77 (0.65–0.92)0.81 (0.71–0.92)0.86 (0.76–0.96)0.91 (0.75–1.11) PLA

  • Relative risk with 95% CIs in parentheses. Comparisons, column versus row, should be read from left to right, and are ordered relative to their overall efficacy. The intervention in the top left position is ranked as best after the network meta-analysis of direct and indirect effects. Direct comparisons are provided above the drug labels, and indirect comparisons are below. Boxes shaded green denote a statistically significant difference.

  • *Highlights the difference between the direct and indirect comparison of VED 300 mg vs ADA 160/80 mg in terms of inconsistency modelling results.

  • ADA, adalimumab; ETR, etrolizumab; FIL, filgotinib; GOL, golimumab; IFX, infliximab; OZA, ozanimod; PLA, placebo; TOF, tofacitinib; UPA, upadacitinib; UST, ustekinumab; VED, vedolizumab.